Menu
Back to User profile » Dr Daniel Duprez
Papers published by Dr Daniel Duprez:
Racial Differences and Contributory Cardiovascular and Non-Cardiovascular Risk Factors Towards Chronic Kidney Disease Progression
Choi Y, Jacobs Jr DR, Kramer HJ, Shroff GR, Chang AR, Duprez DA
Vascular Health and Risk Management 2023, 19:433-445
Published Date: 12 July 2023
Variable and Severe Phenotypic Expression of the “Lebanese Allele” in Two Sisters with Familial Hypercholesterolemia
Chahine J, Kreykes S, Van't Hof JR, Duprez D, Nijjar P
Vascular Health and Risk Management 2021, 17:415-419
Published Date: 21 July 2021
Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
Duprez DA, Handelsman Y, Koren M
Vascular Health and Risk Management 2020, 16:403-418
Published Date: 7 October 2020
Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study
Blaes AH, Mulrooney DA, Vogel RI, Solovey A, Hebbel R, Peterson BA, Neglia JP, Biewen C, Konety SH, Duprez DA
Vascular Health and Risk Management 2018, 14:205-211
Published Date: 10 September 2018
Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy
Blaes AH, Rehman A, Vock DM, Luo X, Menge M, Yee D, Missov E, Duprez D
Vascular Health and Risk Management 2015, 11:591-594
Published Date: 24 November 2015
Heart transplantation and arterial elasticity
Colvin-Adams M, Harcourt N, LeDuc R, Raveendran G, Sonbol Y, Wilson R, Duprez D
Transplant Research and Risk Management 2014, 6:1-7
Published Date: 23 December 2013
Correlation of natriuretic peptides and inferior vena cava size in patients with congestive heart failure
Hebl V, Zakharova MY, Canoniero M, Duprez D, Garcia S
Vascular Health and Risk Management 2012, 8:213-218
Published Date: 10 April 2012
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
Duprez D, Ferdinand K, Purkayastha D, Samuel R, Wright R
Vascular Health and Risk Management 2011, 7:701-708
Published Date: 24 November 2011